1. In Vivo
  2. >>Deal-Making

Biopharma Quarterly Dealmaking Statistics, Q3 2015

A look at financing, M&A and alliance activity July–September 2015

 
• By Maureen Riordan and Amanda Micklus

Biopharma financing totaled $9.7 billion, almost half from follow-on public offerings; there was big consolidation in the generics and health services industries. AstraZeneca signed a dozen partnerships, many of which focused on oncology.

Third-quarter biopharma financing totaled $9.7 billion from 139 deals, a 37% decrease from Q2's $15.4 billion (from 194 deals). (See Exhibit 1.) Even though numbers were down, 20% of the Q3 transactions reached $100 million or greater and the average deal value was $70 million. (In comparison, 18% of the Q2 financings were $100 million or greater, while the average deal value was $79 million – greatly inflated by Endo International PLC's $2.2 billion FOPO [See Deal]; without including this financing, the Q2 average deal value was $68 million.)

Exhibit 1

More from Deal-Making

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By Jo Shorthouse

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By Jo Shorthouse

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By David Wild

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.